Jiangsu Vcare PharmaTech Co. Ltd.,

Chinese biotech funding backed by venture capital and private equity firms experienced a much-needed uplift over the past few weeks, thanks partly to investor interest in assets with novel modalities

Rare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions

Biotech financing deals in China, backed by venture capital and private equity firms, started to pick up in January and deal sizes also crossed the CNY200m ($28m) mark. Apart from Ji Xing Pharmaceuti